Agoracom Blog Home

Posts Tagged ‘COVID-19’

VIDEO – Cardiol Therapeutics $CRDL Sees Accelerated Growth with NASDAQ Uplisting & Continued COVID-19 Threat $LXRX $MESO $HGEN $TYNA

Posted by AGORACOM at 12:15 PM on Monday, August 16th, 2021

Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.  

Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically producedmanufactured under cGMP and THC free. (less than 10 ppm)

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

This week, the company passed another major milestone, moving from the OTC Markets to a U.S. listing on NASDAQ, under the symbol $CRDL – the same as its TSX symbol.

And with the COVID-19 Delta Variant running rampant through North America, Cardiol’s work has become more important than ever.

We sat down with David Elsley, Cardiol Therapeutics’ President & CEO, to discuss the uplisting…

Maitri Health Technologies $MTEC Chosen for U.K. Trade Mission $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM at 2:35 PM on Tuesday, April 20th, 2021
Maitri Health Technologies MTEC
  • British Columbia government selects Maitri as provincial HealthTech leader; Virtual event designed to open doors, facilitate partnerships, expand business

VANCOUVER, BC , April 20, 2021 /CNW/ – Maitri Health Technologies Corp. (” Maitri “) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced it has been asked by the British Columbia Ministry of Jobs, Economic Recovery & Innovation to join a government-supported virtual trade mission to the United Kingdom.

The virtual trade mission will showcase an exclusive group of innovative B.C. HealthTech companies which are expanding business and development in the U.K., the world’s fifth largest economy.

“We’re honoured to be selected by B.C. Trade and Invest to represent B.C. HealthTech leadership,” said Andrew Morton , CEO of Maitri. “A government-supported trade mission can help opens doors, make connections and accelerate our existing European efforts to expand awareness and drive sales.”

“The timing is also opportune to help a market in transition. The U.K. is ramping up vaccinations but still fighting the long-term spread of COVID-19. Our digital strategy is to help protect people today with data intelligence and transition into to a fully functioning economy. Our goal is to provide a safe return to workplaces with long-term security that they stay open,” said Morton.

The trade mission, scheduled for April 26-30 , will be delivered in association with GTM Global and Vita Healthcare Solutions. B.C. Trade and Invest, which chose just 15 companies to participate, helps provincial companies access the U.K. markets and facilitate new partnerships.

Read More: https://agoracom.com/ir/MaitriHealthTechnologies/forums/discussion/topics/759354-maitri-health-technologies-chosen-for-u-k-trade-mission/messages/2312670#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF BioCloud adds Leading Canadian Manufacturing Partner $LXG

Posted by AGORACOM-JC at 8:14 AM on Monday, April 19th, 2021
  • Announced the addition of Danby Appliances to its BioCloud manufacturing team and a manufacturing strategic partnership between Kontrol, OES Inc. and Danby
  • The strategic partnership will mean that OES will handle global supply chain, project engineering and production of the electronic components and Danby will focus on final assembly and scaling production

TORONTO , April 19, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce the addition of Danby Appliances (” Danby “) to its BioCloud manufacturing team and a manufacturing strategic partnership between Kontrol, OES Inc. (” OES “) and Danby. The strategic partnership will mean that OES will handle global supply chain, project engineering and production of the electronic components and Danby will focus on final assembly and scaling production.

“We continue to add to the infrastructure essential to build BioCloud into a global solution for real-time viral detection,” says Paul Ghezzi , CEO Kontrol. “We’re pleased to welcome Danby, one of Canada’s leading manufacturers, to the team. It’s exciting to have them on-board and part of the plan to mass produce BioCloud in Ontario .”

Danby is a Canadian company with a long history of bringing innovative products to market.  Danby’s product manufacturing experience, existing infrastructure in Ontario , and recent success in the mass production of ventilators through the Canadian Ventilator Program will compliment OES’ expertise in product engineering and complex electronic manufacturing.

“We’re thrilled to partner with Jim Estill and his team at Danby, it’s an exciting made-in- Ontario manufacturing partnership,” says Jeff Stewart , CEO of OES Inc. “Our focus has always been centered on rapid prototype development through product launch and initial manufacturing of the technology. With the anticipated global demand for BioCloud, we knew partnering with another manufacturer experienced in large scale product assembly with existing infrastructure in Ontario to support quick ramp up would be important. “

“We are delighted to have been selected by Kontrol and OES as a strategic partner and to be participating in the production of this innovative and much needed technology,” says Jim Estill , CEO Danby.

About Danby Appliances

A proudly Canadian, privately owned company, Danby is a recognized brand and a world leader of refrigeration and specialty appliance products proudly assembling their products in Ontario, Canada . With a rich history of creating innovative appliance, refrigeration and climate control products, Danby has been at the forefront of revolutionizing smart space living for the past 75 years. Their mission is simple; create simple, functional, and durable products designed to fit consumers at every stage of their life. The combination of smart design, smart craftsmanship, and smart price has been a cornerstone to the success of the Danby family of brands. With more than 2 million units manufactured, assembled, and tested annually, Danby manages a global inventory system tracking tens of thousands of raw material items and SKU’s. For more information about Danby Appliances visit www.danby.com

About OES Inc.

Starting in 1980 OES followed a basic strategy that proved successful; connect with emerging companies with market growth opportunities, fill their need for a technology partner and design, produce and support innovative solutions that exceeded expectations and business goals.

It was a strategy that created limitless opportunities for diversity and OES quickly became involved in projects that included electrical engineering as well as assembly, installation, and service for solutions in various markets and industries. As OES engaged with customers around the world and applied their talents to designing innovative electronic and technology applications, their growth and problem solver reputation led to the creation of three diverse yet related divisions – OES Manufacturing, OES Scoreboards and OES Technologies.

Over the years, OES has developed trusted advisor relationships across multiple markets and industries worldwide. OES’ reputation for innovation and rapid prototyping is second only to OES’ reputation for unmatched customer service. Continued success is driven by striving for absolute customer satisfaction and embracing 4F’s – Fast, Focused, Flexible, and Finish – every single day. For more information about OES Inc. visit www.oes-inc.com

About Kontrol BioCloud TM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Technologies provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date.  Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Rowing Canada Aviron teams up with Kontrol $KNR $KNR.ca $KNR.c $KNRLF #BioCloud to protect Olympic and Paralympic hopefuls $LXG

Posted by AGORACOM-JC at 10:42 AM on Tuesday, April 13th, 2021
  • Rowing Canada Aviron is teaming up with Kontrol BioCloud to pilot its Safe Space Technology™ in the National Team Training environment
  • The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19
  • The system will be installed in the erg dome and medical treatment centre at the Pacific Institute for Sport Excellence in Victoria, BC

TORONTO , April 13, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) announces that Rowing Canada Aviron (“RCA”) is teaming up with Kontrol BioCloud to pilot its Safe Space Technology™ in the National Team Training environment. The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19. The system will be installed in the erg dome and medical treatment centre at the Pacific Institute for Sport Excellence in Victoria, BC .

“We developed BioCloud to help us get back to normal across all sectors of the economy, including athletics and sports,” said Kontrol CEO, Paul Ghezzi .  “We are delighted to share our Safe Space Technology with RCA and help create safer spaces for athletes.”

Adding the Biocloud technology into our training centre will add another critical layer of safety and confidence to our existing Covid protocols, ” said Tricia McBride , RCA Lead Physiotherapist. ” This technology will help our medical staff ensure our athletes are training in the safest environment possible and allow our athletes to focus on their training without worrying about the air they are breathing.

National team rowers have been training under strict COVID-19 protocols since the re-opening of the National Training Centre last May. Protocols include small training groups, masking, social distancing, handwashing, and thorough sanitizing of all equipment. The trialing of this innovative technology will further enhance the safety of these environments and ensure that our Olympic and Paralympic hopefuls can continue focusing on their training in the lead up to Tokyo . www.rowingcanada.org.

About Kontrol BioCloud TM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com .

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Technologies provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com

Maitri Health Technologies $MTEC.ca Announces Chief Technology Officer $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM at 8:51 AM on Monday, April 12th, 2021
Maitri Health Technologies MTEC

VANCOUVER, BC , April 12, 2021 /PRNewswire/ – Maitri Health Technologies Corp. (” Maitri “) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced Andrew McCann, a digital innovator in cloud platforms and online user experiences, is joining as Chief Technology Officer (CTO).

Mr. McCann was a co-founder of DeviantArt, one of the first social media networks, and served as CTO until the company was acquired by Wix.com Ltd. (NASDAQ: WIX). During tenure as CTO, DeviantArt was a Hollywood -based online platform with over 40-million users and the world’s largest catalog of user created online images. At it’s peak, DeviantArt handled traffic of over two billion page views per month, requiring incredibly sophisticated data management and development.

Mr. McCann’s entrepreneurial innovations began earlier, when he co-founded Silicon Valley-based MediaScience Inc., acquired by Lycos, now part of Brightcom Group Ltd. (NSE: BCM), and built Sonique, one of the world’s first, and eventually second biggest, desktop audio players.

Mr. McCann has advised to health-tech companies, AI start-ups and does mentoring work with Creative Destruction Labs.

Read More: https://agoracom.com/ir/MaitriHealthTechnologies/forums/discussion/topics/758871-maitri-health-technologies-announces-chief-technology-officer/messages/2311574#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Provides BioCloud Manufacturing Capacity Update $LXG

Posted by AGORACOM-JC at 8:51 AM on Wednesday, March 31st, 2021
  • Received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units.
  • To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met, which includes the increase of manufacturing capacity to 20,000 units per month.
  • Confirming that it has met the conditions precedent for the final $800,000 in funding

TORONTO , March 31, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) is pleased to provide an update on its manufacturing capacity as it relates to various milestones for the Ontario Together Fund.

As a follow up to the press release dated February 4 th , 2021, CEM Specialties Inc. (” CEMSI “), a wholly owned subsidiary of Kontrol Technologies, received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units. To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met,  which includes the increase of manufacturing capacity to 20,000 units per month.

The Company will deliver a final package to the Ontario Together Fund in the next week, confirming that it has met the conditions precedent for the final $800,000 in funding, including the required manufacturing capacity. Manufacturing capacity is the ability to manufacture a certain number of units per month and is not a sales forecast. The final $800,000 funding balance is issued at the discretion of the Ontario Together Fund following the Company’s submission.

“As we initiated commercial production, we have made continuous improvements to the manufacturing of BioCloud,” says Paul Ghezzi , CEO of Kontrol. “Some of these improvements relate to a reduction in sizing of internal systems, reduction of electronic boards and overall streamlining of installation. This is part of the normal process of moving from individual prototypes to commercial production. We have done so in a short period of time with great effort from the entire team.”

“We have made great progress with BioCloud manufacturing,” says Jeff Stewart , CEO of OES Inc. “Through our internal capacity and the addition of manufacturing capacity with our Ontario based strategic manufacturing partners we are pleased to be able to deliver up to 20,000 units per month in manufacturing capacity.”

Global Supply Chain

Currently the global supply chain for the majority of components used in the manufacturing of BioCloud appears to be stabilizing. However, lead times on electronic components and semi-conductors, which are subject to competition from the automotive and mobile industry, have been a challenge. The Company reviews the global supply chain with its manufacturing partner OES Inc. on a routine basis. The Company has no control over potential delays and lead times in the global supply chain.

“I am proud of our team which has worked tirelessly to design and develop a technology with the primary goal of assisting in the reduction of transmittance of the SARS-CoV-2 virus and its variants through earlier detection,” says Gary Saunders , President of Kontrol BioCloud. “In addition to vaccines, technologies which can provide early alerting systems are important to help us create safer spaces and get back to normal across the global economy.”

BioCloud Reagent and Antibodies

The BioCloud unit operates to detect SARS-CoV-2, and other viruses, bacteria and fungi from the air through the use of continuous air sampling and a biological response process. The primary component which makes up the BioCloud proprietary reagent is a specifically formulated combination of antibodies. The antibodies, which are purchased from third party manufacturers, are combined, and tested by independent labs for the reaction to and detection of the SARS-CoV-2 virus.

The Company’s patented antibody cooling chamber utilizes a Peltier element technology to ensure accurate and controlled temperatures are maintained for the entire life cycle of the antibodies. In addition, the Company deploys refrigerated packaging to ensure a specific temperature range is maintained during transportation and shipping of its reagent and antibodies.

The Company continues to review various antibodies from third party manufacturers with the goal to reduce the costs of BioCloud consumables and create a large supply pool to choose from as part of its overall supply chain management.

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/758295-kontrol-provides-biocloud-manufacturing-capacity-update/messages/2310425#message

Kontrol Technologies $KNR $KNR.ca $KNR.c $KNRLF Announces Intended Normal Course Issuer Bid $LXG

Posted by AGORACOM-JC at 7:00 PM on Wednesday, March 24th, 2021
  • Intends to implement a normal course issuer bid (“NCIB”) through the facilities of the Canadian Securities Exchange (CSE) or alternative trading systems.
  • On any given day, during the NCIB, Kontrol may only purchase up to 69,500 common shares, which is equivalent to 25% of the Average Daily Trading Volume of 278,000 calculated based on the trading volumes on the CSE over the past 12 months and may purchase once per calendar week, in a block trade, a greater number of Common Shares.

TORONTO , March 24, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) is pleased to announce today that it intends to implement a normal course issuer bid (“NCIB”) through the facilities of the Canadian Securities Exchange (CSE) or alternative trading systems.

Pursuant to the NCIB, Kontrol may purchase, from time to time, over a period of 12 months starting March 25, 2021 and ending March 25, 2022 , up to 2,061,236 common shares (approx. 5% of its common shares issued and outstanding as of March 24, 2021 ). As of March 24, 2021 , there were 41,224,731 common shares of Kontrol issued and outstanding. On any given day, during the NCIB, Kontrol may only purchase up to 69,500 common shares, which is equivalent to 25% of the Average Daily Trading Volume of 278,000 calculated based on the trading volumes on the CSE over the past 12 months and may purchase once per calendar week, in a block trade, a greater number of Common Shares.

Purchases under the NCIB may commence as of March 25, 2021 and will end on the earlier of: (i) March 25, 2022 ; or (ii) the date on which the Company has purchased the maximum number of common shares to be acquired under the NCIB. All purchases made by the Company will be through PI Financial Corporation acting on behalf of the Company. The purchases will be made in accordance with the rules of the CSE, through the facilities of the CSE or through alternative trading systems. The actual number of common shares which will be purchased, and the timing of such purchases, will be determined by the Company, and the price which the Company will pay for the common shares will be the market price at the time of the purchase. The common shares purchased under the NCIB will be cancelled.

The Company’s Board of Directors believes that the market price of the Company’s common shares may from time to time not reflect the underlying value of the Company, specifically its growth opportunities, and that the proposed purchasing of its common shares is in the best interests of the Company and represents an appropriate use of corporate funds. It is expected that any purchases made by the Company could also enhance value and liquidity for its shareholders.

Of note, this NCIB is further to a previous NCIB that the Company had implemented while trading under the CSE. Under the previous NCIB, which started on July 8, 2019 and ended on July 8, 2020 , 1,464,156 common shares were approved for purchase, of which 30,500 common shares were purchased. The weighted average price paid per common share purchased was $0.58 CDN.

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com .

http://facebook.com/KontrolTechCorp/https://twitter.com/kontrolgrouphttps://www.linkedin.com/company/kontrol-group

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud are subject to the risk that the Kontrol BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications. Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date.  Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies $MTEC.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM at 9:56 AM on Tuesday, March 23rd, 2021
Maitri Health Technologies MTEC
  • Bridget Ross brings extensive experience in MedTech development and services;
  • Joins advisory board of healthcare, logistics, capital markets and innovation leaders

VANCOUVER, BC , March 23, 2021 /PRNewswire/ – Maitri Health Technologies Corp. (” Maitri “) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board.

Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel -based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and the Canadian Consulate Technology Accelerator, in Boston , MA. 

For three decades, she held several executive roles at the world’s largest broadly based healthcare company, Johnson & Johnson (J&J).

“Bridget brings an unmatched level of experience and success to Maitri’s extended team,” said Andrew Morton, CEO of Maitri. “Maitri is uniquely positioned to modernize healthcare systems for governments, healthcare systems and businesses to function well beyond the pandemic. Bridget’s counsel and insights on product development will be invaluable as we continue to evolve and execute our integrated PPE and technology strategy.”

Read More: https://agoracom.com/ir/MaitriHealthTechnologies/forums/discussion/topics/757866-former-johnson-johnson-executive-joins-advisory-board-at-maitri-health-technologies/messages/2309370#message

Canadian Sport Institute Pacific teams up with Kontrol $KNR $KNR.ca $KNR.c $KNRLF #BioCloud to help protect Canada’s #Olympic and Paralympic hopefuls on the road to Tokyo $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 9:18 AM on Tuesday, March 23rd, 2021
  • Canadian Sport Institute Pacific (CSI Pacific) is teaming up with Kontrol BioCloud to operate its Safe Space Technology™ in the National Team Training environment.
  • The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19.
  • The system will be installed at Canadian Sport Institute Pacific’s Whistler Athletes Centre in Whistler, BC

TORONTO , March 23, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) announces that Canadian Sport Institute Pacific (CSI Pacific) is teaming up with Kontrol BioCloud to operate its Safe Space Technology™ in the National Team Training environment. The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19. The system will be installed at Canadian Sport Institute Pacific’s Whistler Athletes Centre in Whistler, BC 

We developed BioCloud to help us get back to normal across all sectors of the economy, including athletics and sports.  We are delighted to share our Safe Space Technology with Canadian Sport Institute Pacific ,” says Paul Ghezzi , CEO of Kontrol Technologies Corp.

CSI Pacific works closely with a large number of Olympic and Paralympic hopefuls training in British Columbia , and throughout a wide variety of sports.  These athletes and coaches have been training under strict COVID-19 protocols throughout the pandemic. Protocols include small training groups, masking, social distancing, handwashing, and thorough sanitizing of all equipment.

CSI Pacific identified athletes are exempt from the Government of British Columbia’s public health order, which has created opportunities for high performance athletes to train, compete and travel within the province. This is a huge opportunity for B.C. to support athletes and CSI Pacific thanks the Government of British Columbia for making this consideration. This opportunity is also how Kontrol BioCloud can provide an additional benefit to these athletes.

“CSI Pacific’s staff have been working diligently throughout COVID to help keep these athletes healthy and safe as they prepare to represent Canada at the Tokyo Olympics and Paralympics,” says Dr. Paddy McCluskey , CSI Pacific’s Chief Medical Officer. “We are excited to add the BioCloud device to our safety measures as it will give athletes confidence that they are training in a safe space.”

The trialing of the BioCloud technology will further enhance the safety of these environments and ensure that Canada’s Olympic and Paralympic hopefuls can continue focusing on their training in the lead up to Tokyo .
Athletes registered with CSI Pacific are upholding an extremely high standard of COVID safety by training in bubbles and undergoing testing to ensure safety in and around the training environment. CSI Pacific staff are upholding the same level of safety for the protection of the athletes, coaches and each other in order to minimize the disruption to training and competition for the athletes. CSI Pacific would like to thank all athletes for following the protocols so diligently.

Kontrol, both directly and through its growing global distribution network, has identified athletics, sports and sporting venues as an important vertical to establish safe spaces.

About CSI Pacific – (Canadian Sport Institute Pacific): Powering Performance. Inspiring Excellence.

Offering world-class Olympic and Paralympic training environments in Vancouver , Whistler and Victoria , Canadian Sport Institute Pacific is committed to Powering Performance. Inspiring Excellence. Working with national sport organizations and fuelled by our national and provincial partners such as Sport Canada, viaSport, Own the Podium, Canadian Olympic Committee, Canadian Paralympic Committee and the Coaches Association of Canada , we are driven by our mantra to Collaborate. Serve. Innovate. Perform.

Our team of sport science, sport medicine, coaching & life services experts provide leading-edge programs and services to athletes and coaches to ensure they have every advantage to win medals for Canada .
www.csipacific.ca

About Kontrol BioCloud TM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, athletics, mass transportation and other. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com .

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Technologies provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com

Foyer Richelieu Welland to install Kontrol $KNR $KNR.ca $KNR.c $KNRLF BioCloud to enhance safe spaces in Long Term Care $SNE $MSFT $GOOGL $QCOM

Posted by AGORACOM-JC at 2:45 PM on Friday, March 19th, 2021
  • Announced that Foyer Richelieu Welland, a long-term care facility In Welland, Ontario , is teaming up with Kontrol BioCloud to install and showcase Kontrol BioCloud in operation
  • The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19
  • Kontrol BioCloud is a Safe Space Technology TM

TORONTO , March 19, 2021 – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) is pleased to announce that Foyer Richelieu Welland, a long-term care facility In Welland, Ontario , is teaming up with Kontrol BioCloud to install and showcase Kontrol BioCloud in operation. The Kontrol BioCloud viral detection technology is designed as a real-time analyzer to detect airborne pathogens, such as COVID-19.  Kontrol BioCloud is a Safe Space Technology TM .

We developed BioCloud to help us get back to normal across all sectors of the economy, Including long-term care facilities and retirement homes.  We are delighted to share our Safe Space Technology and provide real-time viral monitoring for Foyer Richelieu Welland, ” said Paul Ghezzi , CEO of Kontrol Technologies Corp.

Foyer Richelieu Welland has been following strict COVID-19 protocols and has an established track record of creating safe spaces for its residents and staff. Protocols include masking, social distancing, handwashing, and thorough sanitizing of all equipment.

“We take the safety and our residents and staff as a top organizational priority. We are committed to safer spaces for all and the ability to add real-time monitoring through Kontrol’s BioCloud technology is of great interest.” said Sean Keays , Directeur général chez Foyer Richelieu Welland.

About Kontrol BioCloud TM

BioCloud is a real-time analyzer designed to detect airborne viruses.  With a proprietary detection chamber that can be replaced as needed, viruses are detected, and a silent alert system is created in the Cloud or over local intranet. BioCloud’s applications include classrooms, offices, retirement homes, long term care, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com .

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/757672-foyer-richelieu-welland-to-install-kontrol-biocloud-to-enhance-safe-spaces-in-long-term-care/messages/2308970#message